Epithelial Cell Cytology in Breast Cancer Risk Assessment
This document governs BCBSOK reimbursement for cytologic analysis of epithelial cells used to assess breast cancer risk and management of high-risk patients; it applies to providers submitting claims to Blue Cross and Blue Shield of Oklahoma and to members covered under BCBSOK plans.
Document updated with literature review; Reimbursement Information unchanged.
Revised statement to indicate all cytological analysis for breast cancer diagnosis is not reimbursable and added codes 88172, 88173, 88177.
New policy created.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.